Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine

Technical Summary: Serotype Skewing and Immune Imprinting Shape Response to the Tetravalent Dengue Virus Qdenga Vaccine

Problem Statement
Dengue virus (DENV) remains a critical global health threat, with approximately 390 million infections annually. The development of effective vaccines has been historically hindered by the necessity for balanced tetravalent immunity (covering all four serotypes) and the risk of antibody-dependent enhancement (ADE) in seronegative individuals. While Qdenga (TAK-003) is the only widely available tetravalent dengue vaccine, its immunological profile, particularly regarding the impact of the vaccine's DENV-2 backbone and the phenomenon of immune imprinting (where prior exposure shapes subsequent responses), remains incompletely defined. Previous efficacy trials suggested broad immunogenicity but relied on binary seropositivity thresholds that may obscure response magnitude and breadth. There is a critical need to characterize the real-world immunological dynamics of Qdenga, including its performance in older adults (≥65 years), a population excluded from initial trials, and to determine if the vaccine elicits balanced protection or skewed responses.

Methodology
The authors conducted a longitudinal immunological study in Brazil involving 110 adults from dengue-endemic regions. The cohort was stratified by baseline DENV serostatus (naïve vs. exposed), sex, and age (including a significant proportion of older adults, 65–90+ years). Participants received two doses of Qdenga three months apart.

• Sample Collection: Plasma and peripheral blood mononuclear cells (PBMCs) were collected at baseline (T0), before the second dose (T1), and at 7 (T2) and 60 (T3) days post-second dose.
• Humoral Immunity: Neutralizing antibody titers were measured using focus reduction neutralization tests (FRNT) against both the vaccine strains and contemporary circulating DENV isolates. Antibody binding was assessed via whole-virion ELISA. Complement-mediated neutralization was also evaluated.
• Cellular Immunity: B and T cell dynamics were profiled using flow cytometry. Activation-induced marker (AIM) assays were employed to quantify virus-specific CD4+ and CD8+ T cell responses following stimulation with DENV-specific peptide pools.
• Analysis: The study utilized unsupervised hierarchical clustering and t-SNE to identify response patterns without predefined groupings. Random forest analysis determined the importance of demographic and immunological variables. Responses were defined by magnitude (fold-change from baseline) and breadth (number of serotypes eliciting a ≥3-fold increase).

Key Contributions and Results

1. Serostatus-Dependent and Serotype-Skewed Humoral Responses:

   • Imprinting vs. Backbone: The study reveals that vaccine-induced immunity is heavily shaped by two factors: pre-existing immune imprinting in exposed individuals and the DENV-2 backbone in naïve individuals.
   • DENV-Naïve Individuals: Only 8% of DENV-naïve participants developed tetravalent neutralizing responses. Approximately one-third responded to a single serotype, almost exclusively DENV-2. Neutralization against DENV-4 remained uniformly poor across all groups.
   • DENV-Exposed Individuals: These individuals mounted broader responses, but the hierarchy was dictated by their baseline serotype-specific immunity (e.g., those with baseline DENV-1 dominance maintained DENV-1 dominance post-vaccination).
   • Kinetics: Neutralizing antibody titers plateaued after the first dose, with no substantial increase observed following the second dose.

2. Cellular Immunity:

   • Qdenga elicited robust B cell activation and memory formation, characterized by the expansion of activated (CD27+CD180+) and memory B cell subsets, with stronger responses in previously exposed individuals.
   • Virus-specific T cell responses (both CD4+ and CD8+) were induced in both naïve and exposed groups, independent of age, sex, or baseline serostatus. However, the magnitude of T cell responses did not correlate inversely with poor antibody breadth, suggesting cellular immunity does not compensate for the lack of balanced humoral responses.

3. Performance in Older Adults:

   • The study included older adults (≥65 years), a group excluded from efficacy trials. While seropositive older adults responded comparably to younger counterparts, seronegative older adults exhibited intermediate neutralization responses—higher than younger seronegatives but still skewed toward DENV-2.
   • The vaccine was generally well-tolerated in this age group, with reactogenicity profiles similar to younger participants.

4. Clustering and Determinants:

   • Unsupervised clustering identified five distinct participant profiles based on neutralization capacity. Clusters with high titers were predominantly DENV-exposed, while low-titer clusters were largely DENV-naïve.
   • Random forest analysis confirmed that baseline serostatus and age were the primary determinants of neutralization capacity, whereas sex and prior yellow fever vaccination were not significant factors.

Significance and Claims
The authors claim that their findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga. The study demonstrates that the vaccine's DENV-2 backbone drives type-2-biased responses in naïve individuals, while immune imprinting reinforces pre-existing serotype hierarchies in exposed individuals. Consequently, the vaccine fails to overcome the "imprinting" effect to generate uniform protection across all serotypes, particularly DENV-4.

The paper concludes that these limitations have important implications for deployment strategies, suggesting that:

• Immunological history (serostatus) must be considered when evaluating vaccine performance.
• The consistently poor response to DENV-4 raises concerns about the completeness of tetravalent coverage.
• The lack of significant enhancement after the second dose suggests a potential need for booster strategies, possibly using heterologous vaccines (e.g., Butantan-DV) specifically designed to improve DENV-4 immunogenicity.

The study emphasizes that while Qdenga induces cellular and humoral responses, the breadth and balance of these responses are constrained by both the vaccine design and the host's immune history, necessitating careful monitoring of vaccine effectiveness in diverse populations.